$IGC Pharma (IGC.US)$IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
IGC Pharma (NYSE American:IGC) has announced the enrollment of patients at Baycrest Academy for Research and Education in Toronto, Canada, for its ongoing Phase 2 trial of IGC-AD1, a treatment for agitation in Alzheimer's dementia. IGC-AD1 is a partial CB1 receptor agonist with anti-neuroinflammatory properties, targeting key pathways involved in Alzheimer's disease patho...